



Vivimed

Date: 25th September, 2017

To
BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam


Sub: Incorporation of a step-down Subsidiary in Mauritius– reg.

Ref: Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Please find the attached disclosure in relation to the Incorporation of Vivimed Labs (Mascarene) Ltd in Mauritius by Vivimed Labs Mauritius Ltd (100% wholly owned Subsidiary of Vivimed Labs Ltd)

You are requested to take note of the same.

Yours faithfully
For Vivimed Labs Limited


Company Secretary



Vivimed Labs Ltd. (Corporate Office)

CIN: L02411KA1988PLC009465

North End, Road No. 2,

Banjara Hills, Hyderabad, Telangana - 500 034, India.

T +91(0) 40 6608-6608

contact@vivimedlabs.com | www.vivimedlabs.com

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars							
1.	Name of the Target entity, details in brief such as size, turnover etc.	Vivimed Labs (Mascarene) Ltd, Mauritius Size, Turnover: Not applicable						
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired	Yes						
3.	Industry to which Target entity being acquired belongs	Investment/ Holding/ Dealing in Chemicals and Pharmaceuticals						
4.	Objects and effects of acquisition	The Company will target investment in companies dealing or trading directly / indirectly in Chemical, Pharma and Medicinal products. The Company may also acquire shares in other companies of the Vivimed Group as part of internal restructuring exercise.						
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None						
6.	Indicative time period for completion	Expected to close by December 31, 2017						
7.	Nature of consideration	Cash						
8.	Percentage of shareholding/ control acquired and/ or number of shares acquired	100% through its Wholly owned Subsidiary (Vivimed Labs Mauritius Ltd)						
9.	Cost of acquisition or the price at which the shares are acquired	USD 1000 (USD One thousand Only)						
10.								
a.	Products/line of business acquired	Dealing in Chemicals and Pharmaceuticals						
b.	Date of incorporation	29.08.2017						
c.	History of last 3 years turnover	<table border="1"> <tr> <td>FY 2015-16</td> <td>NA</td> </tr> <tr> <td>FY 2014-15</td> <td>NA</td> </tr> <tr> <td>FY 2013-14</td> <td>NA</td> </tr> </table>	FY 2015-16	NA	FY 2014-15	NA	FY 2013-14	NA
FY 2015-16	NA							
FY 2014-15	NA							
FY 2013-14	NA							
d.	Country in which the acquired entity has presence	Mauritius						
e.	Any other significant information	No						